Skip to content
OpenCapital
Get started

Ionis Pharmaceuticals IONS Research Development And Patent Expense

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept ions:ResearchDevelopmentAndPatentExpense.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's research development and patent expense.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's research development and patent expense?
Ionis Pharmaceuticals (IONS) reported research development and patent expense of $210.17M in Q1 2026.
How has Ionis Pharmaceuticals's research development and patent expense changed year-over-year?
Ionis Pharmaceuticals's research development and patent expense increased by 4.7% year-over-year, from $200.76M to $210.17M.
What is the long-term trend for Ionis Pharmaceuticals's research development and patent expense?
Over 3 years (2021 to 2024), Ionis Pharmaceuticals's research development and patent expense has grown at a 11.9% compound annual growth rate (CAGR), from $643.45M to $901.53M.